Because β-catenin binds tightly to the cytoplasmic domain of type I cadherins, such as E-cadherin, and plays an essential role in the actin cytoskeletal organization (27), the LRRC4/PIK3R1 axis may inhibit the intrinsic invasive ability of ovarian cancer cells to and reduce tumor metastasis behavior by disrupting cell-cell junctions via the AKT/GSK-3β/β-catenin/E-cadherin signaling mechanism. Here, GSK3B is linked to ovarian cancer.